

## Wistar Institute grants Horizon exclusive license , 9/16

**September 2016**—Horizon Discovery Group and the Wistar Institute announced that Horizon has taken an exclusive license to 153 of Wistar’s melanoma patient-derived xenograft models. Horizon’s distribution of the Wistar melanoma PDX collection will allow scientists worldwide to investigate the efficacy and safety of its drugs prior to trials in human populations.

Wistar is providing a selection of PDX models representative of all previously described melanoma subtypes. Horizon will offer this collection as ungrafted PDX suspensions or as the basis of in vivo efficacy studies, where clients provide test compounds and Horizon’s team of expert scientists will demonstrate their effect on PDXs grown in mice.

[Horizon Discovery](#), +44 (0) 1223 655 580